Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
HOLX Hologic
74.385
+0.535+0.72%
YOY
Do not show
Hide blank lines
(FY)2022/09/24(Q4)2022/09/24(Q3)2022/06/25(Q2)2022/03/26
Total revenue
-13.66% 4.86B -27.59% 953.3M -14.17% 1B -6.63% 1.44B
Operating revenue
-13.66% 4.86B -27.59% 953.3M -14.17% 1B -6.63% 1.44B
Cost of revenue
1.57% 1.87B -10.19% 438.7M -2.96% 452.9M 8.26% 489.1M
Gross profit
-21.03% 3B -37.86% 514.6M -21.64% 549.8M -12.82% 946.6M
Operating expense
4.09% 1.37B -9.93% 344.5M -5.57% 320.5M 16.75% 352.7M
Selling and administrative expenses
4.38% 1.04B -12.90% 256.5M -6.08% 244.2M 23.37% 271.9M
-Selling and marketing expense
12.31% 630.3M 0.06% 159.2M 6.73% 152.3M 30.34% 171.4M
-General and administrative expense
-5.89% 407.7M -28.14% 97.3M -21.65% 91.9M 13.05% 100.5M
Research and development costs
2.57% 283.4M -0.65% 76M -5.65% 65.1M -2.80% 69.5M
Depreciation amortization depletion
7.11% 45.2M 4.35% 12M 7.69% 11.2M 10.78% 11.3M
-Depreciation and amortization
7.11% 45.2M 4.35% 12M 7.69% 11.2M 10.78% 11.3M
Operating profit
-34.32% 1.63B -61.83% 170.1M -36.69% 229.3M -24.22% 593.9M
Net non-operating interest income expense
10.85% -82.2M 34.67% -14.7M 4.25% -20.3M -3.81% -21.8M
Non-operating interest income
821.43% 12.9M 4,600.00% 9.4M 500.00% 2.4M 166.67% 800K
Non-operating interest expense
1.60% 95.1M 6.17% 24.1M 5.09% 22.7M 6.10% 22.6M
Other net income (expense)
233.78% 39.6M 4.00% -12M 1,225.71% 39.4M -87.08% 2.3M
Special income (charges)
135.95% 8.7M -378.69% -29.2M 1,061.11% 34.6M -98.47% 200K
-Less:Restructuring and merger&acquisition
-1,526.92% -37.1M -75.41% 1.5M -1,061.11% -34.6M 98.47% -200K
-Less:Impairment of capital assets
-- 27.7M -- 27.7M -- -- -- --
-Less:Other special charges
-96.76% 700K -- -- -- -- -- --
Other non- operating income (expenses)
672.22% 30.9M 368.75% 17.2M 4,700.00% 4.8M -55.32% 2.1M
Income before tax
-32.73% 1.59B -65.08% 143.4M -26.40% 248.4M -26.41% 574.4M
Income tax
-41.76% 286.2M -69.80% 24.7M -71.18% 20M -26.32% 118.7M
Net income
-30.36% 1.3B -63.90% 118.7M -14.81% 228.4M -26.43% 455.7M
Net income continuous Operations
-30.36% 1.3B -63.90% 118.7M -14.81% 228.4M -26.43% 455.7M
Minority interest income
0 0 0 0
Net income attributable to the parent company
-30.43% 1.3B -63.90% 118.7M -14.90% 228.4M -26.49% 455.7M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-30.43% 1.3B -63.90% 118.7M -14.90% 228.4M -26.49% 455.7M
Basic earnings per share
-28.85% 5.18 -63.57% 0.47 -13.33% 0.91 -24.58% 1.81
Diluted earnings per share
-28.85% 5.13 -63.28% 0.47 -13.46% 0.9 -24.37% 1.8
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
Unqualified Opinion------

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
CEO: Mr. Stephen P. Macmillan
Market: NASDAQ
Listing Date: 03/02/1990
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist